Tailored therapies for triple-negative breast cancer: current landscape and future perceptions
Naunyn-Schmiedeberg s Archives of Pharmacology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 3, 2025
Язык: Английский
The Interplay of Mitochondrial Dysfunction in Oral Diseases: Recent Updates in Pathogenesis and Therapeutic Implications
Al-Hassan Soliman Wadan,
Mohamed Abdelsattar Ahmed,
Abdelnaser Hussein Ahmed
и другие.
Mitochondrion,
Год журнала:
2024,
Номер
78, С. 101942 - 101942
Опубликована: Авг. 6, 2024
Язык: Английский
Response of different infection models in broiler chickens against supplemental Organic acid – A review
Microbial Pathogenesis,
Год журнала:
2025,
Номер
unknown, С. 107527 - 107527
Опубликована: Апрель 1, 2025
Язык: Английский
Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria
Archives of Microbiology,
Год журнала:
2025,
Номер
207(3)
Опубликована: Фев. 13, 2025
Язык: Английский
Characteristics and Outcomes of Patients Treated with Carbapenem Versus Non-carbapenem Therapy for AmpC-Producing Enterobacterales Bacteremia: A Retrospective Study
Infectious Diseases and Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
Inducible
AmpC
β-lactamases
in
Gram-negative
Enterobacterales
pose
therapeutic
challenges.
Although
carbapenems
are
the
preferred
treatment,
other
antibiotics
can
serve
as
a
viable
alternative.
Studies
comparing
treatment
options
report
varied
outcomes.
This
study
evaluates
30-day
mortality,
failure,
and
length
of
hospitalization
patients
with
AmpC-producing
bacteremia.
retrospective
cohort
included
adult
bacteremia
caused
by
Enterobacterales.
Exclusion
criteria
included:
therapy
duration
<
72
h,
coinfection,
resistant
isolates,
death
within
h
diagnosis.
Patients
were
divided
into
definitive
carbapenem
noncarbapenem
therapy.
The
primary
outcome
was
while
secondary
outcomes
evaluated
failure
hospitalization.
Statistical
analysis
used
descriptive
statistics,
group
comparisons,
logistic
regression.
Of
214
screened
patients,
80
met
inclusion
criteria.
Enterobacter
cloacae
(60%)
predominant
pathogen,
primarily
originating
from
line-related
infections
(55%).
Carbapenems
empirical
(45%)
(75%)
therapies;
mortality
higher
non-carbapenem
(20%
versus
3.3%,
p
=
0.08).
Treatment
significantly
1.6%,
0.01).
mean
hospital
stay
longer
(26
±
38.40
days)
than
(11.15
7.15
days,
0.87).
Older
age
associated
(odds
ratio
(OR)
1.07,
95%
confidence
intervals
(CI):
0.98-12.20,
0.015).
Carbapenem
use
improved
survival,
highlighting
its
importance
strategies.
Age
affects
stressing
need
for
personalized
treatments.
Further
research
strategies
needed
to
address
clinical
failures
enhance
antimicrobial
stewardship.
Язык: Английский
A Review of In Silico and In Vitro Approaches in the Fight Against Carbapenem‐Resistant Enterobacterales
Journal of Clinical Laboratory Analysis,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
ABSTRACT
Objectives
The
rise
in
carbapenem‐resistant
Enterobacterales
(CRE)
has
reinforced
the
global
quest
for
developing
effective
therapeutics.
Traditional
drug
discovery
approaches
have
been
inadequate
overcoming
this
challenge
due
to
their
resource
and
time
constraints.
Methods
English
literature
was
searched
by
structured
queries
related
our
review
between
January
1,
2020,
December
31,
2024.
Results
key
resistance
mechanisms
CRE,
such
as
enzymatic
hydrolysis,
decreased
permeability,
efflux
pump
overexpression,
examined
review.
Computational
technologies
become
pivotal
discovering
novel
antimicrobial
agents
with
improved
accuracy
efficiency.
Besides
this,
highlights
advances
structure‐
ligand‐based
identifying
potential
drugs
against
CRE.
Recent
studies
demonstrating
use
of
silico
techniques
develop
targeted
CRE
also
explored.
Moreover,
underscores
significance
integrating
both
vitro
counter
Enterobacterales,
supported
latest
studies.
However,
these
promising
computational
a
few
major
drawbacks,
lack
standardized
parameterization,
potentially
false
positives,
complexity
clinical
translations.
regulatory
barriers
restrict
progress
new
antimicrobials
market
approval.
Conclusion
inhibitor
is
gaining
popularity,
it
can
be
expedited
refining
them
reliable
validation.
innovative
hybrid
need
hour
tackle
mitigate
threat
resistance.
Язык: Английский
Insight into bioactive glass and bio-ceramics uses: unveiling recent advances for biomedical application
Discover Materials,
Год журнала:
2025,
Номер
5(1)
Опубликована: Апрель 25, 2025
Язык: Английский
The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders
Naunyn-Schmiedeberg s Archives of Pharmacology,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 5, 2025
Abstract
The
modulation
of
gut
microbiota
presents
promising
therapeutic
possibilities
for
various
health
conditions,
ranging
from
gastrointestinal
infections
to
neurodegenerative
and
mental
disorders.
Among
the
available
interventions,
modulators
(GMMs)
such
as
probiotics
prebiotics
have
demonstrated
significant
potential
in
infection
prevention
neuroprotection.
Despite
these
encouraging
findings,
clinical
application
GMMs
remains
challenging
due
safety
concerns
inconsistent
effectiveness
across
diverse
patient
populations.
These
factors
create
substantial
barriers
widespread
adoption
microbiota-based
therapies
practice.
To
overcome
challenges
fully
leverage
modulation,
this
review
explores
feasibility
repurposing
managing
multiple
A
broad
spectrum
microbiota-targeted
strategies
is
examined,
including
dietary
modifications,
fecal
transplantation,
bacteriophage
therapy,
microbiome
engineering,
immune
system
modulation.
particularly
innovative
approach
involves
integrating
with
pharmaceutical
delivery
systems
enhance
efficacy
while
mitigating
adverse
effects.
This
integrative
strategy
underscores
pivotal
role
disease,
supporting
development
precision
medicine
tailored
individual
needs.
By
combining
targeted
mechanisms,
not
only
improves
treatment
but
also
addresses
critical
regarding
variability.
Furthermore,
outlines
future
research
directions
within
rapidly
evolving
field
emphasizing
necessity
comprehensive
trials
long-term
evaluations.
critically
assessing
both
opportunities
associated
study
provides
a
strategic
framework
translating
experimental
into
viable
applications.
holistic
has
redefine
paradigms,
offering
personalized
wide
range
disorders
advancing
broader
medicine.
Язык: Английский